OncLive.com· @OncLive · X·· 1 天前评分70
正文 · 机器翻译
开始了！！第二场主席研讨会已正式拉开帷幕。今晚请回来观看 Krascendo 1、SAFFRON、CLARITY-Gastric 01 和 HARMONi-GI1 的现场报道 @myESMO #ESMO26 #Oncology
111 浏览 · 0 赞 · 0 转发 · 0 回复
会议摘要
CLARITY-Gastric 02: A randomised phase 3 study of sonesitatug vedotin (Sone-Ve) and capecitabine with or without rilvegostomig in Claudin18.2 positive (CLDN18.2+) advanced or metastatic gastric, gastroesophageal junction, or oesophageal ade
https://esmocongress.esmo.orgKrascendo 3: A randomised, phase III trial in progress of divarasib vs immunotherapy or observation in patients with resected, stage II-IIIB, KRAS G12C+ non-small cell lung cancer
https://esmocongress.esmo.org来源：OncLive.com · x.com